Company: CERO
Filing Date: 2025-02-07
Form Type: 424B3
Source: 0001213900-25-011071
Chunk: 409

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-02-07
Form: 424B3
Chunk 409
---
 ability to continue as a going concern
is dependent on its ability to raise additional capital to fund its research and development (“R&D”) activities and meet
its obligations on a timely basis. Since inception, the Company has incurred net losses and operating cash flow deficits, resulting in
an accumulated deficit of $43.1 million as of December 31, 2023. Additional funds are necessary to maintain current operations and
to continue R&D activities. However, there can be no assurance that sufficient funding will be available to allow the Company to
successfully continue its R&D activities and planned regulatory filings with the Food and Drug Administration (“FDA”).
If the Company is unable to obtain necessary funds, significant reductions in spending and the delay or cancellation of planned activities
may be necessary. These actions would have a material adverse effect on the Company’s business, results of operations, and prospects.
These conditions raise substantial doubt about the Company’s ability to continue as a going concern within one year from the date
these financial statements are issued. The accompanying financial statements do not include any adjustments relating to the recoverability
and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of this
uncertainty.

Risks and uncertainties– The Company
is subject to all of the risks inherent in an early-stage biotechnology company. These risks include, but are not limited to, limited
management resources, intense competition, and dependence upon the availability of cash to sustain operations. The Company’s operating
results may be materially affected by the foregoing factors.

The Company’s research also requires approvals
from the FDA prior to beginning clinical trials and prior to product commercialization. There can be no assurance that the Company’s
current ongoing research and future clinical development will result in the granting of these required approvals. If the Company is denied
such approvals or such approvals are substantially delayed, they could have a material adverse effect upon the Company’s future
financial results and cash flows.

NOTE 2 – Significant Accounting Policies

Use of estimates– The preparation
of financial statements in conformity with accounting principles generally accepted in the United States of America (“U.S.”)
requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent
liabilities at the date of the financial statements, and the reported amounts of expenses incurred during the reporting period. Items
subject to such estimates and assumptions include the estimates of the fair values of convertible preferred stock, common stock, and
preferred stock warrant liability, stock-based compensation expense